Generation Bio Management
Management criteria checks 3/4
Generation Bio's CEO is Geoff McDonough, appointed in Oct 2017, has a tenure of 6.58 years. total yearly compensation is $2.32M, comprised of 27.2% salary and 72.8% bonuses, including company stock and options. directly owns 2.74% of the company’s shares, worth $5.66M. The average tenure of the management team and the board of directors is 3 years and 6.4 years respectively.
Key information
Geoff McDonough
Chief executive officer
US$2.3m
Total compensation
| CEO salary percentage | 27.2% |
| CEO tenure | 6.6yrs |
| CEO ownership | 2.7% |
| Management average tenure | 3yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Dec 07Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth
Jul 11We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Mar 11Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
Nov 19We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Aug 05Generation Bio GAAP EPS of -$0.66 misses by $0.04
Aug 04Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
Apr 20Generation Bio: High-Risk, Medium-To-Low-Reward
Dec 30We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Nov 11We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Jul 28Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Mar 08Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares
Jan 14
Generation Bio's insiders on buying spree, stock +4%
Jan 13Generation Bio prices equity offering at $24.50
Jan 07Generation Bio files to offer 7.5M shares
Jan 04Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?
Dec 27Generation Bio EPS misses by $0.01
Nov 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$630k | -US$127m |
| Sep 30 2023 | n/a | n/a | -US$124m |
| Jun 30 2023 | n/a | n/a | -US$127m |
| Mar 31 2023 | n/a | n/a | -US$134m |
| Dec 31 2022 | US$4m | US$606k | -US$137m |
| Sep 30 2022 | n/a | n/a | -US$135m |
| Jun 30 2022 | n/a | n/a | -US$136m |
| Mar 31 2022 | n/a | n/a | -US$129m |
| Dec 31 2021 | US$6m | US$583k | -US$119m |
| Sep 30 2021 | n/a | n/a | -US$112m |
| Jun 30 2021 | n/a | n/a | -US$101m |
| Mar 31 2021 | n/a | n/a | -US$88m |
| Dec 31 2020 | US$2m | US$516k | -US$81m |
| Sep 30 2020 | n/a | n/a | -US$72m |
| Jun 30 2020 | n/a | n/a | -US$68m |
| Mar 31 2020 | n/a | n/a | -US$65m |
| Dec 31 2019 | US$593k | US$424k | -US$61m |
Compensation vs Market: Geoff's total compensation ($USD2.32M) is above average for companies of similar size in the US market ($USD1.61M).
Compensation vs Earnings: Geoff's compensation has been consistent with company performance over the past year.
CEO
Geoff McDonough (53 yo)
6.6yrs
Tenure
US$2,315,263
Compensation
Dr. Cameron Geoffrey McDonough, also known as Geoff, M.D. serves as Independent Director of Third Harmonic Bio, Inc. since March 2024. He had been an Independent Director of Surface Oncology, Inc. since Fe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.6yrs | US$2.32m | 2.74% $ 5.7m | |
| Chief Financial Officer | 3.8yrs | US$1.14m | 0.079% $ 163.1k | |
| Chief Scientific Officer | 5yrs | US$1.15m | 0.37% $ 759.4k | |
| Chief Legal Officer & Secretary | 1.1yrs | US$1.21m | 0.014% $ 29.3k | |
| Co-Founder | 7.6yrs | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Chief Operating Officer | 2.3yrs | no data | 0.021% $ 42.8k | |
| Chief Human Resources Officer | 1.2yrs | no data | no data | |
| Chief Strategy Officer | 1.7yrs | no data | 0.17% $ 352.6k |
3.0yrs
Average Tenure
50yo
Average Age
Experienced Management: GBIO's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.6yrs | US$2.32m | 2.74% $ 5.7m | |
| Independent Chairman | 6.6yrs | US$181.21k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$143.71k | 0.20% $ 407.4k | |
| Independent Director | 5.8yrs | US$151.21k | 0.80% $ 1.7m | |
| Independent Director | 6.4yrs | US$143.71k | 0.24% $ 500.1k | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.4yrs | US$143.71k | 0.32% $ 662.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.2yrs | US$144.21k | 0.014% $ 29.5k | |
| Independent Director | 6.4yrs | US$143.71k | 0.071% $ 147.3k | |
| Member of Scientific Advisory Board | 5.6yrs | no data | no data |
6.4yrs
Average Tenure
60yo
Average Age
Experienced Board: GBIO's board of directors are considered experienced (6.4 years average tenure).